Members and contact

Janne Rothmar Herrmann is Professor with special responsibilities in health law and technology at the Faculty of Law, University of Copenhagen. She is also governor of the World Association of Medical Law and member of the Danish Dataethics Council. Recent and ongoing work within the topics of reproductive rights, abortion, health data and assisted reproduction. Currently engaged in a research project on “Technologies of Death and Dying at the Beginning of Life” and a research project on “Reconceptualising Reproductive Rights”.

Tuija-Maija Takala is currently working as a research director at the Aalto university Department of Management Studies. She is also an adjunct professor at the University of Helsinki at the Faculty of Social Sciences and supervisor for doctoral programme in Philosophy, Arts, and Society. Among other positions of trust, she has been the President of the European Society for Philosophy of Medicine and Health Care (2011-2013), a member of the Research Ethics Committee of Aalto University (2018-2021) and a Permanent Expert in Philosophical Bioethics Finnish Office for Health Technology Assessment / National Research and Development Center for Welfare and Health (2006-2016).

She is a professor of imaging neuroscience at Aalto University, Finland. Her primary field is cognitive neuroscience, with original training up to PhD in physics. She currently serves as member of the Finnish National Board on Research Integrity (TENK). Her research focuses on determining how noninvasive functional neuroimaging methods can be used informatively to characterise neural and cognitive processing in humans, with a special emphasis on the neural organisation of language function.

He has a Ph.D. in philosophy, specialising in moral and political philosophy as well as applied ethics. Fields of interest include autonomy and informed consent in contexts of health care and research, professional ethics, reproductive ethics, nursing ethics, criminal justice ethics, and media ethics. Currently engaged in research on the democratic role and function of universities.

Gudrun Valdimarsdóttir obtained her PhD degree in molecular biology from Uppsala University. She is associate professor at the faculty of medicine, University of Iceland. Her research focus lies within the field of human embryonic stem cells and cardiovascular development and disease, including tumour angiogenesis. Gudrun is a board member of the Biomedical Center, University of Iceland and a member of the International Society of Stem Cell Research (ISSCR).

Eirik Joakim Tranvåg work as a senior advisor in the Norwegian Biotechnology Advisory Board. He is a medical doctor with a PhD in medical ethics and priority setting, where he investigated the relationship between personalized medicine and concepts of fairness. He has a special interest in regulation and priority setting of new treatments and technologies, like gene therapy, xenotransplantation and advanced reproductive technologies. Other fields of interests are global health and biotechnology, clinical ethics and genetic testing.

Kerstin Nilsson is a senior professor of obstetrics and gynecology at Örebro University. She is chair of the board of the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), and a board member of the Swedish Society for Obstetrics and Gynecology. She has previously been a member of the Swedish Medical Society’s board and its chairman during 2014-2016. Her research has been clinical studies in the research fields of gynecological endocrinology and urogenital diseases.

Madeleine Hayenhjelm has a PhD in philosophy and is a senior lecturer in practical philosophy at Umeå University. Fields of interests: ethical theory and ethical aspects of risk, public policy, and uncertain outcomes. Current topics include the moral dimensions of precaution, the human germline as a moral boundary, moral reparations, and reparability as a moral constraint. She is currently involved in a three-year research project on the ethical aspects of the gene-editing tool CRISPR/Cas9.